Management of myeloma-associated renal dysfunction in the era of novel therapies

Expert Review of Hematology

Volumn 5, Issue 1, 2012, Pages 51-68

  Gaballa, Mahmoud R ^a   Laubach, Jacob P ^b   Schlossman, Robert L ^b   Redman, Katherine ^b   Noonan, Kimberly ^b   Mitsiades, Constantine S ^b   Ghobrial, Irene M ^b   Munshi, Nikhil ^b   Anderson, Kenneth C ^b   Richardson, Paul G ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Jerome Lipper Multiple Myeloma Center   (United States)

Author keywords

bortezomib; dexamethasone; lenalidomide; multiple myeloma; renal dysfunction; thalidomide

Indexed keywords

ALLOPURINOL; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; PREDNISONE; RASBURICASE; THALIDOMIDE; POMALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; AMYLOIDOSIS; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER INCIDENCE; CANCER PATIENT; CANCER RELAPSE; CREATININE BLOOD LEVEL; DEHYDRATION; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEVER; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HEPATOSPLENOMEGALY; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; KIDNEY DYSFUNCTION; LYMPHADENOPATHY; MULTIPLE MYELOMA; PARESTHESIA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ACUTE KIDNEY TUBULE NECROSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; GLOMERULOSCLEROSIS; HEMODIALYSIS PATIENT; HEMODYNAMIC MONITORING; KIDNEY BIOPSY; KIDNEY FUNCTION; LIGHT CHAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SPLENOMEGALY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PREDNISONE; PYRAZINES; RENAL INSUFFICIENCY; THALIDOMIDE;

EID: 84856261003     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.72     Document Type: Review

References (130)

1. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78(1), 21-33 (2003). (Pubitemid 36033957)
2. Sakhuja V, Jha V, Varma S et al. Renal involvement in multiple myeloma: a 10-year study. Ren. Fail. 22(4), 465-477 (2000). (Pubitemid 30441642)
3. Heher EC, Goes NB, Spitzer TR et al. Kidney disease associated with plasma cell dyscrasias. Blood 116(9), 1397-1404 (2010).
4. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516-2520 (2008).
5. Munshi NC. Plasma cell disorders: an historical perspective. Hematology Am. Soc. Hematol. Educ. Program 2008(1), 297 (2008).
6. Augustson BM, Begum G, Dunn JA et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. 23(36), 9219-9226 (2005).
7. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 374(9686), 324-339 (2009).
8. Coleman EA, Lynch H, Enderlin C et al. Initial report of a family registry of multiple myeloma. Cancer Nurs. 32(6), 456-464 (2009).
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
10. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur. J. Haematol. 53(4), 207-212 (1994). (Pubitemid 24347964)
11. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22(8), 1485-1493 (2008).
12. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J. Clin. Oncol. 23(15), 3412-3420 (2005).
13. Annesley TM, Burritt MF, Kyle RA. Artifactual hypercalcemia in multiple myeloma. Mayo Clin. Proc. 57(9), 572-575 (1982). (Pubitemid 13254060)
14. Pozzi C, D'amico M, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am. J. Kidney Dis. 42(6), 1154-1163 (2003). (Pubitemid 37486758)
15. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121(5), 749-757 (2003).
16. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 28(33), 4976-4984 (2010).
17. Hutchison CA, Plant T, Drayson M et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 9, 11 (2008).
18. Van Rhee F, Bolejack V, Hollmig K et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110(3), 827-832 (2007). (Pubitemid 47267417)
19. Bradwell AR, Carr-Smith HD, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47(4), 673-680 (2001). (Pubitemid 32275810)
20. Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M. The ultrastructural basis of renal pathology in monoclonal gammopathies. J. Nephrol. 18(6), 659-675 (2005). (Pubitemid 43085432)
21. Batuman V, Guan S. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am. J. Physiol. 272(4 Pt 2), F521-F530 (1997).
22. Batuman V, Verroust PJ, Navar GL et al. Myeloma light chains are ligands for cubilin (gp280). Am. J. Physiol. 275(2 Pt 2), F246-F254 (1998).
23. Cohen G, Horl WH. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin. Dial. 22(4), 369-372 (2009).
24. Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int. 62(6), 1977-1988 (2002). (Pubitemid 35366153)
25. Sanders PW, Herrera GA, Galla JH. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int. 32(6), 851-861 (1987). (Pubitemid 18015516)
26. Ma CX, Lacy MQ, Rompala JF et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 104(1), 40-42 (2004). (Pubitemid 38879834)
27. Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW. Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 117(4), 1301-1307 (2011).
28. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann. Intern. Med. 112(6), 455-464 (1990). (Pubitemid 20098527)
29. Zhou P, Comenzo RL, Olshen AB et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 111(7), 3403-3406 (2008).
30. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 11(1), 27-42 (1997). (Pubitemid 27147744)
31. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 16(6), 1182-1188 (2002). (Pubitemid 34618857)
32. Smolens P, Barnes JL, Kreisberg R. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. J. Lab. Clin. Med. 110(4), 460-465 (1987). (Pubitemid 18029912)
33. Benabe JE, Martinez-Maldonado M. Hypercalcemic nephropathy. Arch. Intern. Med. 138(5), 777-779 (1978). (Pubitemid 9011731)
34. Kjellstrand CM, Cambell DC 2nd, Von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch. Intern. Med. 133(3), 349-359 (1974).
35. Rieselbach RE, Bentzel CJ, Cotlove E, Frei E 3rd, Freireich EJ. Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Pathogenesis and therapy of uric acid nephropathy. Am. J. Med. 37, 872-883 (1964).
36. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch. Pathol. Lab. Med. 128(8), 875-879 (2004). (Pubitemid 39014119)
37. Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. QJM 90(12), 773-780 (1997). (Pubitemid 28008950)
38. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch. Intern. Med. 150(4), 863-869 (1990). (Pubitemid 20122064)
39. Pozzi C, Pasquali S, Donini U et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin. Nephrol. 28(1), 1-9 (1987). (Pubitemid 17154313)
40. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin. Proc. 58(10), 665-683 (1983). (Pubitemid 13019381)
41. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light chain deposition. Am. J. Med. 60(2), 293-299 (1976).
42. Prakash J, Niwas SS, Parekh A et al. Multiple myeloma - presenting as acute kidney injury. J. Assoc. Physicians India 57, 23-26 (2009).
43. Kleber M, Ihorst G, Deschler B et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur. J. Haematol. 83(6), 519-527 (2009).
44. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur. J. Haematol. 65(3), 175-181 (2000).
45. Niesvizky R, Badros AZ. Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. J. Natl Compr. Canc. Netw. 8(Suppl. 1), S13-S20 (2010).
46. Gleason C, Nooka A, Lonial S. Supportive therapies in multiple myeloma. J. Natl Compr. Canc. Netw. 7(9), 971-979 (2009).
47. Minnema MC, Van Der Spek E, Van De Donk NW, Lokhorst HM. New developments in the treatment of patients with multiple myeloma. Neth. J. Med. 68(1), 24-32 (2010).
48. Ludwig H, Beksac M, Blade J et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15(1), 6-25 (2010).
49. Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma. Curr. Treat. Options Oncol. 4(3), 239-246 (2003).
50. Tosi P, Zamagni E, Cellini C et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur. J. Haematol. 73(2), 98-103 (2004). (Pubitemid 38980109)
51. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5), 417-421 (2004). (Pubitemid 38610244)
52. Joazeiro CA, Anderson KC, Hunter T. Proteasome inhibitor drugs on the rise. Cancer Res. 66(16), 7840-7842 (2006). (Pubitemid 44299143)
53. Hideshima T, Chauhan D, Hayashi T et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22(52), 8386-8393 (2003). (Pubitemid 37523890)
54. Richardson PG, Hideshima T, Mitsiades C, Anderson K. Proteasome inhibition in hematologic malignancies. Ann. Med. 36(4), 304-314 (2004). (Pubitemid 38789285)
55. Eda H, Aoki K, Kato S et al. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells. Eur. J. Haematol. 85(1), 68-75 (2010).
56. Sarkozi R, Perco P, Hochegger K et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J. Pharmacol. Exp. Ther. 327(3), 645-656 (2008).
57. Hideshima T, Ikeda H, Chauhan D et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114(5), 1046-1052 (2009).
58. Roccaro AM, Hideshima T, Raje N et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66(1), 184-191 (2006). (Pubitemid 43166024)
59. Petrucci MT, Ricciardi MR, Gregorj C et al. Effects of IL-6 variants in multiple myeloma: growth inhibition and induction of apoptosis in primary cells. Leuk. Lymphoma 43(12), 2369-2375 (2002). (Pubitemid 35390335)
60. Kumar S, Witzig TE, Timm M et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 17(10), 2025-2031 (2003). (Pubitemid 37322133)
61. Vanderkerken K, Vande Broek I, Eizirik DL et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin. Exp. Metastasis 19(1), 87-90 (2002). (Pubitemid 34208358)
62. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol. Dial. Transplant. 21(7), 1855-1862 (2006). (Pubitemid 43985713)
63. Terpos E, Katodritou E, Tsiftsakis E et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 94(3), 372-379 (2009).
64. Mulkerin D, Remick S, Ramanathan R et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. J. Clin. Oncol. 24(18 Suppl.), 2032 (2006).
65. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005). (Pubitemid 41007864)
66. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10), 3557-3560 (2007). (Pubitemid 350159621)
67. Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 103(6), 1195-1200 (2005). (Pubitemid 40328090)
68. San-Miguel JF, Richardson PG, Sonneveld P et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX Phase 3 study. Leukemia 22(4), 842-849 (2008). (Pubitemid 351552634)
69. Morabito F, Gentile M, Ciolli S et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur. J. Haematol. 84(3), 223-228 (2010).
70. Chanan-Khan AA, Kaufman JL, Mehta J et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109(6), 2604-2606 (2007). (Pubitemid 46425908)
71. Roussou M, Kastritis E, Migkou M et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk. Lymphoma 49(5), 890-895 (2008). (Pubitemid 351942741)
72. Li J, Zhou DB, Jiao L et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin. Lymphoma Myeloma 9(5), 394-398 (2009).
73. Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a Phase II study. J. Clin. Oncol. 28(30), 4635-4641 (2010).
74. Dimopoulos MA, Richardson PG, Schlag R et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the Phase III VISTA study. J. Clin. Oncol. 27(36), 6086-6093 (2009).
75. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92(10), 1411-1414 (2007). (Pubitemid 350144160)
76. Malani AK, Gupta V, Rangineni R. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol. 116(4), 255-258 (2006). (Pubitemid 44795905)
77. Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J. Kidney Dis. Transpl. 21(1), 63-68 (2010).
78. Oakervee H, Popat R, Cavenagh JD. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk. Lymphoma 48(10), 1910-1921 (2007). (Pubitemid 47542977)
79. Knight R. IMiDs: a novel class of immunomodulators. Semin. Oncol. 32(4 Suppl. 5), S24-S30 (2005). (Pubitemid 41111987)
80. Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1), 210-216 (2001).
81. Hayashi T, Hideshima T, Akiyama M et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 128(2), 192-203 (2005).
82. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9), 3063-3067 (2002). (Pubitemid 35217050)
83. Chen N, Lau H, Kong L et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47(12), 1466-1475 (2007). (Pubitemid 350115306)
84. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007). (Pubitemid 350146108)
85. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007). (Pubitemid 350146107)
86. Dimopoulos MA, Christoulas D, Roussou M et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur. J. Haematol. 85(1), 1-5 (2010).
87. Weber D, Wang M, Chen C et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 Phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. ASH Annual Meeting Abstracts 108(11), 3547 (2006).
88. Wang M, Dimopoulos MA, Chen C et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12), 4445-4451 (2008).
89. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk. Lymphoma 49(6), 1108-1115 (2008). (Pubitemid 351943257)
90. Niesvizky R, Naib T, Christos PJ et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Haematol. 138(5), 640-643 (2007). (Pubitemid 47206719)
91. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177(6), 1675-1680 (1993). (Pubitemid 23146134)
92. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91(9), 4082-4085 (1994). (Pubitemid 24139577)
93. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol. 28(6), 607-612 (2001). (Pubitemid 33134420)
94. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer 42(11), 1612-1622 (2006). (Pubitemid 44118763)
95. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12), 4525-4530 (2002). (Pubitemid 34627223)
96. Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr. Drug Metab. 7(6), 677-685 (2006). (Pubitemid 44226590)
97. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
98. Kneller A, Raanani P, Hardan I et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br. J. Haematol. 108(2), 391-393 (2000). (Pubitemid 30143656)
99. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol. 109(1), 89-96 (2000). (Pubitemid 30340583)
100. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87(4), 408-414 (2002). (Pubitemid 34297548)
101. Arai A, Hirota A, Fukuda T et al. [Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction]. Rinsho Ketsueki 50(4), 295-299 (2009).
102. Seldin DC, Choufani EB, Dember LM et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin. Lymphoma 3(4), 241-246 (2003). (Pubitemid 36416849)
103. Tosi P, Zamagni E, Tacchetti P et al. Thalidomide-dexamethasone as induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol. Blood Marrow Transplant 16(8), 1115-1121 (2010).
104. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467-1473 (2006). (Pubitemid 44264086)
105. Blade J, Fernandez-Llama P, Bosch F et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch. Intern. Med. 158(17), 1889-1893 (1998). (Pubitemid 28440861)
106. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89(7), 826-831 (2004). (Pubitemid 38981342)
107. Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk. Lymphoma 43(2), 351-354 (2002). (Pubitemid 34202115)
108. Fabro S, Smith RL, Williams RT. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215(5098), 296 (1967).
109. Kastritis E, Anagnostopoulos A, Roussou M et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92(4), 546-549 (2007). (Pubitemid 350144300)
110. Dimopoulos MA, Roussou M, Gavriatopoulou M et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin. Lymphoma Myeloma 9(4), 302-306 (2009).
111. Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann. Hematol. 89(3), 291-297 (2010).
112. Roussou M, Kastritis E, Christoulas D et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk. Res. 34(10), 1395-1397 (2010).
113. Clark WF, Stewart AK, Rock GA et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann. Intern. Med. 143(11), 777-784 (2005).
114. Hutchison CA, Cockwell P, Reid S et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J. Am. Soc. Nephrol. 18(3), 886-895 (2007). (Pubitemid 46434505)
115. Hutchison CA, Bradwell AR, Cook M et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin. J. Am. Soc. Nephrol. 4(4), 745-754 (2009).
116. Hutchison CA, Cockwell P, Stringer S et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J. Am. Soc. Nephrol. 22(6), 1129-1136 (2011).
117. Adam Z, Krejci M, Tichy M, Stepankova S, Pour L, Hajek R. [The treatment of renal failure in multiple myeloma]. Vnitr. Lek. 55(6), 570-582 (2009).
118. Sanders PW. A new twist in myeloma treatment. Blood 107(2), 413-414 (2006). (Pubitemid 43076350)
119. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008-5014 (2009).
120. Richardson PG, Siegel D, Baz R et al. A Phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH Annual Meeting Abstracts 116(21), 864 (2010).
121. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 12(6), 664-689 (2007). (Pubitemid 47036203)
122. Laubach JP, Mitsiades CS, Mahindra A et al. Novel therapies in the treatment of multiple myeloma. J. Natl Compr. Canc. Netw. 7(9), 947-960 (2009).
123. Pasquali S, Zucchelli P, Casanova S et al. Renal histological lesions and clinical syndromes in multiple myeloma. Renal Immunopathology Group. Clin. Nephrol. 27(5), 222-228 (1987). (Pubitemid 17068076)
124. Ivanyi B. Renal complications in multiple myeloma. Acta Morphol. Hung. 37(3-4), 235-243 (1989). (Pubitemid 20352394)
125. Montseny JJ, Kleinknecht D, Meyrier A et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol. Dial. Transplant. 13(6), 1438-1445 (1998). (Pubitemid 28254318)
126. Herrera GA. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch. Pathol Lab. Med. 133(2), 249-267 (2009).
127. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82(12), 3712-3720 (1993). (Pubitemid 24006055)
128. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4(4), 314-322 (2004). (Pubitemid 38525287)
129. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br. J. Haematol. 132(4), 385-397 (2006). (Pubitemid 43381614)
130. Multiple Myeloma: Translational and Emerging Therapies. Anderson KC, Ghobrial IM (Eds). Informa Healthcare, NY, USA (2007).